Has Nicholas Bozarth, PA received payments from drug or device companies?

Yes. Drug and device makers reported $3,211 in general payments to Nicholas Bozarth, PA across 180 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nicholas Bozarth, PA did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nicholas Bozarth, PA come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nicholas Bozarth, PA

Medical · Post Falls, IDNPI 1326440827

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,538 and has fallen 93.8% since, to $95 in 2025.

$3,211in general payments, 2019–2025

Across 180 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$641
Pfizer$355
Lilly USA, LLC$336
Johnson & Johnson$236
Amgen$234
AstraZeneca$161
plus $1K from 23 others

What the payments were for

Food & beverage$3,12697%
Education$853%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	45	$641
Pfizer	18	$355
Lilly USA, LLC	23	$336
Johnson & Johnson	12	$236
Amgen	11	$234
AstraZeneca	8	$161
GSK	9	$134
Astellas Pharma US Inc	3	$119
Boehringer Ingelheim	5	$111
Novartis	5	$106
Exact Sciences	4	$95
Novo Nordisk	6	$94
Sanofi-aventis U.S. LLC	5	$85
Bayer	3	$56
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	3	$56
Biohaven Pharmaceutical Holding Company Ltd.	2	$53
Biohaven Pharmaceuticals, Inc.	2	$45
Takeda Pharmaceuticals U.S.A., Inc.	2	$38
Sanofi Pasteur Inc.	2	$36
Medtronic	1	$32
Abbott	2	$31
E.r. Squibb & Sons, L.L.C.	2	$31
Nevro Corp.	1	$22
Dexcom, Inc.	1	$22
Mylan Specialty L.p.	1	$18
Hologic Sales And Service, LLC	1	$17
Daiichi Sankyo Inc.	1	$16
Therapeuticsmd, Inc.	1	$16
Gilead	1	$16

How this compares

$3,211 in reported general payments places this provider in the 85th percentile of 265 medical providers in Idaho.

See all medical providers in Idaho →

Medicare billing

Part B allowed, 2024

$92,618

Medicare patients

222

Services billed

2,377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	28	$30,896
EliquisApixaban	25	$30,685
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	17	$20,572
JardianceEmpagliflozin	18	$17,217
JanuviaSitagliptin Phosphate	16	$14,189
FarxigaDapagliflozin Propanediol	13	$13,792
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	22	$3,093
Atorvastatin Calcium	211	$2,494
Fluticasone-SalmeterolFluticasone Propion/Salmeterol	18	$2,451
Tamsulosin Hcl	86	$2,077
Metoprolol Succinate	86	$1,939
Gabapentin	96	$1,934
Omeprazole	157	$1,759
Rosuvastatin Calcium	45	$1,722
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide	70	$1,697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic	$94	$30,89628 claims
PfizerEliquis	$355	$30,68525 claims
GSKTrelegy Ellipta	$134	$20,57217 claims
Boehringer IngelheimJardiance	$111	$17,21718 claims
AstraZenecaFarxiga	$161	$13,79213 claims
AbbVieSynthroid	$641	$81213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 265 medical providers in Idaho.